Key Clinical Message The combination therapy of Lopinavir/Ritonavir plus Favipiravir might be a treatment option for patients with COVID‐19. Serum ferritin levels and lymphocytopenia are promising markers for disease severity and disease progression that are commonly available in general clinical practice. This is the first report to present a promising anti‐viral combination therapy, Lopinavir/Ritonavir plus Favipiravir, for COVID‐19 patients. Serum ferritin levels and lymphocytopenia might be markers for disease severity and disease progression.
All Keywords
【저자키워드】 COVID‐19, Lopinavir, Ritonavir, Favipiravir, ferritin, lymphocytopenia, 【초록키워드】 Treatment, Lopinavir/ritonavir, disease severity, combination therapy, COVID‐19, Disease progression, clinical, Patient, Clinical practice, marker, COVID‐19 patients, message, ferritin level, 【제목키워드】 coronavirus disease, Pneumonia, COVID‐19, Combination, patients treated,
【저자키워드】 COVID‐19, Lopinavir, Ritonavir, Favipiravir, ferritin, lymphocytopenia, 【초록키워드】 Treatment, Lopinavir/ritonavir, disease severity, combination therapy, COVID‐19, Disease progression, clinical, Patient, Clinical practice, marker, COVID‐19 patients, message, ferritin level, 【제목키워드】 coronavirus disease, Pneumonia, COVID‐19, Combination, patients treated,